Bayer"s stock plummeted over 12% following disappointing third-quarter results and a downward revision of its 2024 guidance, primarily due to struggles in its agriculture sector. The company reported a net loss of €4.18 billion, driven by significant write-downs in its agrochemicals division, which saw an 8.7% revenue decline. While the Pharmaceuticals and Consumer Health divisions showed some growth, overall expectations for 2024 remain cautious, with anticipated declines in profit and a commitment to cost-cutting measures.
Several biopharma companies are implementing significant layoffs as part of restructuring efforts to extend their cash runways. Ovid, Lexicon Pharmaceuticals, Acelyrin, and FibroGen are among those reducing their workforce, with layoffs ranging from 33% to 75% of their staff. These moves follow disappointing clinical trial results and strategic shifts in focus, aiming to optimize resources and ensure continued funding for research and development.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.